Invicta Diagnostic Limited Approves Audited Financial Results for Fiscal Year Ending March 31, 2026
Invicta Diagnostic Limited has announced the approval of its audited financial results for the half year and the full financial year ended March 31, 2026, covering both standalone and consolidated statements.The company's Board of Directors considered and approved the audited financial results, which reflect the operational performance and financial position of the Group during the period.
Standalone Financial Highlights (As on March 31, 2026)
The audited standalone financial results provide a view of the company’s standalone performance. The consolidated audited statement of assets and liabilities for the period reflects the following major figures (in Lakhs):| Particulars | As on March 31, 2026 | As on March 31, 2025 |
|---|---|---|
| Total Shareholders Funds | 499,226 | N/A |
| Total Non-Current Liabilities | 1,817 | 8 |
| Total Current Liabilities | 71,596 | 269.79 |
| TOTAL LIABILITIES | 6,024,87 | 2,121.64 |
| TOTAL NON-CURRENT ASSETS | 259,412 | 148,287 |
| TOTAL CURRENT ASSETS | 283,430 | 49,687 |
| TOTAL ASSETS | 6,024,87 | 2,121.64 |
Consolidated Financial Results and Group Structure
The Board of Directors also approved the audited consolidated financial results for the half year and full financial year ended March 31, 2026. The statement reflects the financial performance of the Group, including the parent company and its subsidiaries and associate entities.The consolidated financial results include the following entities:
| Name of Entity | Relationship |
|---|---|
| Invicta Diagnostic Limited | Parent Company |
| Primacare Healthcare LLP | Subsidiary |
| PCD Diagnostic LLP | Subsidiary |
| Pratham MRI & CT Scan Centre | Subsidiary |
| Invicta Medical LLP | Subsidiary |
| Primacare Diagnostic LLP | Subsidiary |
| Porteus Medical | Subsidiary |
| Shegaon Diagnostic Lp | Subsidiary |
| Invicta Healthplus | Subsidiary |
| Invicta Lifecare LLP | Subsidiary |
| Eriscril:ii Infotech LLP | Associate |
IPO Proceeds Utilization
Regarding the utilization of funds raised through the Initial Public Offer (IPO), the company confirmed that as of March 31, 2026, there is no deviation or variation in the utilization of the funds.The statement on deviation/variation of funds raised through the IPO for the half year and year ended March 31, 2026, shows the following details:
| Object as disclosed in the Offer Document | Amount disclosed in the Offer Document | Actual Utilized Amount | Unutilized Amount |
|---|---|---|---|
| Issue related Expenses | 293.69 | 278.59 | 15.1 |
| Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra | 211,133 | 227.79 | 1,883.54 |
| General Corporate purposes | 407.46 | 238 | 169.46 |
| Total | 2,812.48 | 744.38 | 2,068.1 |
The company noted that the unutilized amount is currently held in Fixed deposit and Current account with banks.
Cash Flow Summary
The statement of cash flows for both the standalone and consolidated operations provides a detailed view of cash generation.Consolidated Statement of Cash Flows (Key Figures):
The total revenue for the year ended March 31, 2026, was reported at 16,947, with a total cash flow from operations (before extraordinary items) reported at 70,754.
Disclaimer
These financial results are based on the audited figures of the full financial year and unaudited year-to-date figures. The company also reported that the first financial results are available following the IPO and are focused on scaling operations and improving margins.INVICTA Stock Price Movement
Invicta Diagnostic Limited shares slipped by 4.98% to close at ₹66.85 on Monday. The stock traded on 110,400 shares for the day, touching a day low of ₹66.85.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: